Document Detail


Druas for Alzheimer's disease: best avoided. No therapeutic advantage.
MedLine Citation:
PMID:  22822592     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
The French Pharmacoeconomic Committee that assesses the medical benefit of new drugs and provides recommendations about reimbursement has downgraded its rating of the medical benefit (SMR, service mddical rendu) provided by cholinesterase inhibitors and memantine in Alzheimer's disease from "major" to "low".
Authors:
-
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  21     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-07-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  France    
Other Details:
Languages:  eng     Pagination:  150     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Next Document:  Gabapentin and pregabalin: abuse and addiction.